V-Link activates the cholinergic anti-inflammatory pathway through non-invasive ear stimulation, avoiding the surgical complexity and training burden of implanted neuromodulation devices.
Clinical research at Washington University in St. Louis linked the approach to reduced cerebral vasospasm, suppressed pro-inflammatory cytokines, and improved functional recovery in critically ill patients.
Aurenar targets the intensive care segment, where secondary inflammation drives complications and excess cost across high-acuity patients.
FDA Breakthrough Device designation for aneurysmal subarachnoid hemorrhage positions V-Link for prioritized regulatory review as the company advances toward a pivotal trial, with indications beyond stroke planned.
Aurenar's lead offering is V-Link, a wireless, single-use ear-worn device that delivers transauricular vagus nerve stimulation to reduce inflammation in intensive care unit patients.
The platform's initial indication is aneurysmal subarachnoid hemorrhage, where it targets cerebral vasospasm and secondary brain injury by activating the body's cholinergic anti-inflammatory pathway without surgical implantation.
